A Cardiologist’s Perspective on Cardiovascular Risk Assessment in Prostate Cancer
Direct insight from a cardiologist on the advent of cardiovascular risk when treating a patient for prostate cancer.
EP: 1.Cardiovascular Disease Risk in Men with Prostate Cancer
EP: 2.Examining the Data From Key Clinical Trials, and Practical Strategies
EP: 3.Strategies for Mitigating Cardiovascular Risk
EP: 4.Summary and Case Study
EP: 5.A Medical Oncologist Reflects on a Typical Prostate Cancer Patient
EP: 6.A Urologist Reflects on a Typical Prostate Cancer Patient
EP: 7.A Cardiologist Reflects on a Typical Prostate Cancer Patient
EP: 8.Practice-Related And Provider-Patient Communication Strategies For Prostate Cancer Care
Now Viewing
EP: 9.A Cardiologist’s Perspective on Cardiovascular Risk Assessment in Prostate Cancer
EP: 10.A Medical Oncologist’s Perspective on Cardiovascular Risk Assessment in Prostate Cancer
EP: 11.Typical Examinations And Tests For Cardiovascular Risk Assessment in a Cardiology Practice
EP: 12.Typical Examinations And Tests For Cardiovascular Risk Assessment in an Oncology Practice
EP: 13.A Cardiologist’s Recommended Interventions For Cardiovascular Risk Mitigation
EP: 14.A Medical Oncologist’s Recommended Interventions For CV Risk Mitigation
EP: 15.Strategies For Communicating Cardiovascular Risk to Patients Starting on ADT
EP: 16.Considerations For ADT Selection And Patient Education on Treatment-Related AEs
EP: 17.A Urologist’s Approach to Followup For Patients on ADT And Practice Communication Strategies
EP: 18.A Cardiologist’s Approach to Followup For Patients on ADT and Strategies in Multidisciplinary Care
EP: 19.A Urologist Reacts to AbbVie’s Educational Video: Key Takeaways And Clinical Impact
EP: 20.A Cardiologist Reacts to AbbVie’s Educational Video: Key Takeaways And Clinical Impact
January 2023 AbbVie Inc. Company Confidential
Recent Videos
Related Content
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Podcast
Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
![A retrospective study shows that [177Lu]Lu-PSMA-617 retreatment led to a median OS of 14.5 months in castration-resistant prostate cancer.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Ff5ef402e3456a83ca4765506f26761d323734d14-446x339.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "A retrospective study shows that [177Lu]Lu-PSMA-617 retreatment led to a median OS of 14.5 months in castration-resistant prostate cancer.")
